J&J Q1 2026 sales rise 9.9% to $24.1 billion and 2026 sales guidance is raised to $100.3-101.3 billion

Johnson & Johnson reported first-quarter 2026 sales of $24.1 billion, up 9.9% reported and 6.4% operationally, with adjusted EPS of $2.70 against $2.77 a year earlier. Innovative Medicine grew 11.2% reported to $15.4 billion and MedTech rose 7.7% to $8.6 billion. The company raised its 2026 outlook to $100.3-101.3 billion of reported sales and $11.45-11.65 of adjusted EPS, and the release says no new acquisitions were announced.

• Q1 2026 sales $24.1 billion, up 9.9% reported; operational growth 6.4%
• Innovative Medicine $15.4 billion, up 11.2% reported; MedTech $8.6 billion, up 7.7% reported
• Adjusted EPS $2.70 versus $2.77 a year earlier; reported EPS $2.14 versus $4.54
• Raised 2026 guidance: reported sales $100.3-101.3 billion, adjusted EPS $11.45-11.65 (both up from January)

SEC filing 8-K · accession 0000200406-26-000076 · sec.gov ↗